RenovaCare Appoints Chief Medical Officer, Dr. Jo Ellen Schweinle, Former Sr. Medical Officer at U.S. Dept. of Health and Human Services

Roseland, NJ – June 10th, 2020 – RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), developer of patented technologies for spraying self-donated stem cells for the regeneration of skin and other organs and tissues, today announced the appointment of its first Chief Medical Officer, Jo Ellen Schweinle, MD.

RenovaCare Strengthens FDA Program with Leading U.S. Regulatory Group and Significant Investment

Roseland, NJ – May 28th, 2020 – RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), developer of patented technologies for spraying self-donated stem cells for the regeneration of skin and other organs and tissues, today announced that it has expanded its engagement with MCRA, the leading U.S. regulatory group for medical devices and biologics, to continue to advance the Company’s FDA program.

RenovaCare Appoints Founding Director of BARDA Dr. Robin A. Robinson to Chief Scientific Officer

Roseland, NJ – May 26th, 2020 – RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), developer of patented technologies for spraying self-donated stem cells for the regeneration of skin and other organs and tissues, today announced that its Vice President, Scientific Affairs, Dr. Robin A. Robinson will now serve in a new and expanded full-time role as the Company’s Chief Scientific Officer.

Spray-on Gene Therapy with RenovaCare SkinGun™ in New Study Underway at King’s College London

Roseland, NJ – March 30th, 2020 – RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), developer of patented technologies for spraying self-donated stem cells for the regeneration of skin and other organs and tissues, today announced that the Company’s novel SkinGun™ is now being used to apply regenerative cells in a preclinical study of new gene therapies, underway at King’s College London.  Researchers are using the SkinGun™ to ultra-gently spray gene-supplemented cells for accelerated wound healing in Recessive Dystrophic Epidermolysis Bullosa (RDEB), a debilitating skin disease which afflicts young children and leads to premature death.

Dr. Emanual Maverakis, Recipient of Presidential Award for Scientists and Engineers, Joins RenovaCare

Scottsdale, AZ – November 26, 2019 – RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), developer of patented technologies for spraying self-donated stem cells for the regeneration of tissues and organs, is pleased to announce the appointment of Dr. Emanual Maverakis to its Board of Advisors. Dr. Maverakis is a renowned professor at the University of California Davis School of Medicine, holding appointments in the Department of Dermatology and in the Department of Medical Microbiology and Immunology.

RenovaCare Appoints Alan L. Rubino as President and CEO

Scottsdale, AZ – November 18, 2019 – RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), developer of patented technologies for spraying self-donated stem cells for the regeneration of tissues and organs, today announced the appointment of  Alan L. Rubino as President and Chief Executive Officer. Mr. Rubino will lead the Company through its next stages of clinical and corporate development and financial growth.

Dr. Frank Gerberick, Procter & Gamble Product Safety Veteran, Joins RenovaCare

Scottsdale, AZ – September 24th, 2019 – RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), developer of patented technologies for spraying self-donated stem cells for the regeneration of tissues and organs, is pleased to announce the appointment of Dr. Frank Gerberick to its Board of Advisors to help advance the Company’s SkinGun™ cell spray technology for the regeneration of human skin.